Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation.

Okeley NM, Toki BE, Zhang X, Jeffrey SC, Burke PJ, Alley SC, Senter PD.

Bioconjug Chem. 2013 Oct 16;24(10):1650-5. doi: 10.1021/bc4002695. Epub 2013 Sep 19.

PMID:
24050213
2.
3.

A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits.

Jin C, Altmann F, Strasser R, Mach L, Schähs M, Kunert R, Rademacher T, Glössl J, Steinkellner H.

Glycobiology. 2008 Mar;18(3):235-41. doi: 10.1093/glycob/cwm137. Epub 2008 Jan 18.

PMID:
18203810
4.

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.

Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, Gill H, Shen BQ, Rubinfeld B, Tibbitts J, Kaur S, Theil FP, Fielder PJ, Khawli LA, Lin K.

Bioconjug Chem. 2011 Oct 19;22(10):1994-2004. doi: 10.1021/bc200212a. Epub 2011 Oct 3.

PMID:
21913715
5.

Advances in the Development of Site-Specific Antibody-Drug Conjugation.

Zhou Q, Kim J.

Anticancer Agents Med Chem. 2015;15(7):828-36. Review.

PMID:
25731178
6.

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, Andreyka J, Stone I, Hamblett KJ, Francisco JA, Carter P.

Protein Eng Des Sel. 2006 Jul;19(7):299-307. Epub 2006 Apr 27.

PMID:
16644914
7.

In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.

Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Passmore D, Chen TH, Chen S, Liu J, Kuhne MR, Srinivasan M, Assad A, Witte A, Graziano RF, King DJ.

Clin Cancer Res. 2009 May 15;15(10):3376-83. doi: 10.1158/1078-0432.CCR-08-3222. Epub 2009 Apr 28.

8.

Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar.

Zhu Z, Ramakrishnan B, Li J, Wang Y, Feng Y, Prabakaran P, Colantonio S, Dyba MA, Qasba PK, Dimitrov DS.

MAbs. 2014;6(5):1190-200. doi: 10.4161/mabs.29889. Epub 2014 Oct 30.

9.

Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC.

Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Misaka H, Iida S, Wakitani M, Konno Y, Yano K, Shitara K, Hosoi S, Satoh M.

Biotechnol Bioeng. 2006 Jul 5;94(4):680-8.

PMID:
16609957
10.

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.

Glycobiology. 2007 Jan;17(1):104-18. Epub 2006 Sep 29. Erratum in: Glycobiology. 2007 Oct;17(10):1030.

PMID:
17012310
11.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG.

J Biol Chem. 2002 Jul 26;277(30):26733-40. Epub 2002 May 1.

12.

Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.

Qu Z, Sharkey RM, Hansen HJ, Shih LB, Govindan SV, Shen J, Goldenberg DM, Leung SO.

J Immunol Methods. 1998 Apr 15;213(2):131-44.

PMID:
9692846
13.

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

Ducry L, Stump B.

Bioconjug Chem. 2010 Jan;21(1):5-13. doi: 10.1021/bc9002019. Review.

PMID:
19769391
14.

Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.

Lyon RP, Meyer DL, Setter JR, Senter PD.

Methods Enzymol. 2012;502:123-38. doi: 10.1016/B978-0-12-416039-2.00006-9.

PMID:
22208984
15.

Linker technologies for antibody-drug conjugates.

Nolting B.

Methods Mol Biol. 2013;1045:71-100. doi: 10.1007/978-1-62703-541-5_5. Review.

PMID:
23913142
16.

Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.

Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.

J Immunol Methods. 2005 Nov 30;306(1-2):93-103. Epub 2005 Oct 3.

PMID:
16236307
17.

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.

Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.

J Immunol Methods. 2005 Nov 30;306(1-2):151-60. Epub 2005 Sep 22.

PMID:
16219319
18.

Modification of monoclonal and polyclonal IgG with palladium (II) coproporphyrin I: stimulatory and inhibitory functional effects induced by two different methods.

Martsev SP, Preygerzon VA, Mel'nikova YI, Kravchuk ZI, Ponomarev GV, Lunev VE, Savitsky AP.

J Immunol Methods. 1995 Oct 26;186(2):293-304.

PMID:
7594629
19.

Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format.

Zuberbühler K, Casi G, Bernardes GJ, Neri D.

Chem Commun (Camb). 2012 Jul 18;48(56):7100-2. doi: 10.1039/c2cc32412a. Epub 2012 Jun 11.

PMID:
22684082
20.

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.

Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M.

Clin Cancer Res. 2007 Mar 15;13(6):1875-82.

Supplemental Content

Support Center